Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial
Peter Gibbs, Philip R. Clingan, Vinod Ganju et al. · Cancer Chemotherapy and Pharmacology · 2010
Cited by 55 works. doi:10.1007/s00280-010-1303-3
Authors
- Peter Gibbs
- Philip R. Clingan
- Vinod Ganju
- Andrew H. Strickland
- Shirley Wong
- Niall Christopher Tebbutt
- Craig R. Underhill
- Richard M. Fox
- Steven P. Clavant
- Minh Pho
- Tracey J. Brown
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
- Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
- KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- CD44: Structure, Function and Association with the Malignant Process
- ELIMINATION OF HYALURONIC ACID FROM THE BLOOD STREAM IN THE HUMAN
- Secondary and tertiary structures of hyaluronan in aqueous solution, investigated by rotary shadowing-electron microscopy and computer simulation. Hyaluronan is a very efficient network-forming polymer
- Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal Cancer